Search
Barinthus Biotherapeutics PLC
BRNSAdd to Watchlist
0.558USD
+0.007+1.29%
Close 07-31 16:00（ET）Quotes delayed by 15 min
22.79MMarket Cap
LossP/E TTM
More Details of Barinthus Biotherapeutics PLC Company
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC Info
Ticker SymbolBRNS
Company nameBarinthus Biotherapeutics PLC
IPO dateApr 30, 2021
CEOEnright (William J)
Number of employees105
Security typeDepository Receipt
Fiscal year-endApr 30
AddressUnit 6-10, Zeus Building, Rutherford Avenue
CityDIDCOT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeOX11 0DF
Phone441865818808
Websitehttps://www.barinthusbio.com/
Ticker SymbolBRNS
IPO dateApr 30, 2021
CEOEnright (William J)
Company Executives of Barinthus Biotherapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Leon Hooftman, M.D.
Dr. Leon Hooftman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
FAQs
Who are the top five shareholders of Barinthus Biotherapeutics PLC?
The top five shareholders of Barinthus Biotherapeutics PLC are: Dr. Geoffrey Lynn
How many institutions hold shares of Barinthus Biotherapeutics PLC (BRNS)?
As of 2026Q1, 32 institutions hold shares of Barinthus Biotherapeutics PLC, with a combined market value of approximately 16.70M, accounting for 40.87% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1943125.00.